Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Brabio 20mg/1ml solution for injection pre-filled syringes
0802040U0BCAAAB
|
Brabio | Glatiramer acetate | Malignant Disease and Immunosuppression | No data available |
|
Braftovi 50mg capsules
0801050CMBBABAB
|
Braftovi | Encorafenib | Malignant Disease and Immunosuppression | No data available |
|
Braftovi 75mg capsules
0801050CMBBAAAA
|
Braftovi | Encorafenib | Malignant Disease and Immunosuppression | No data available |
|
Brigatinib 180mg tablets
0801050CPAAAAAA
|
Brigatinib | Brigatinib | Malignant Disease and Immunosuppression | No data available |
|
Brigatinib 30mg tablets
0801050CPAAABAB
|
Brigatinib | Brigatinib | Malignant Disease and Immunosuppression | No data available |
|
Brigatinib 90mg tablets
0801050CPAAACAC
|
Brigatinib | Brigatinib | Malignant Disease and Immunosuppression | No data available |
|
Brigatinib 90mg tablets and Brigatinib 180mg tablets
0801050CPAAADAD
|
Brigatinib | Brigatinib | Malignant Disease and Immunosuppression | No data available |
|
Brukinsa 80mg capsules
0801050CSBBAAAA
|
Brukinsa | Zanubrutinib | Malignant Disease and Immunosuppression | No data available |
|
Buserelin 5.5mg/5.5ml solution for injection vials(Prostate)
0803042B0AAAAAA
|
Buserelin (Prostate) | Buserelin | Malignant Disease and Immunosuppression | No data available |
|
Busilvex 60mg/10ml concentrate for inf ampoules
0801010B0BCAAAE
|
Busilvex | Busulfan | Malignant Disease and Immunosuppression | No data available |
|
Busulfan 25mg capsules
0801010B0AAAFAF
|
Busulfan | Busulfan | Malignant Disease and Immunosuppression | No data available |
|
Busulfan 2mg/5ml oral liquid
0801010B0AAADAD
|
Busulfan | Busulfan | Malignant Disease and Immunosuppression | No data available |
|
Busulfan 60mg/10ml solution for infusion ampoules
0801010B0AAAEAE
|
Busulfan | Busulfan | Malignant Disease and Immunosuppression | No data available |
|
Busulfan 60mg/10ml solution for infusion vials
0801010B0AAAGAG
|
Busulfan | Busulfan | Malignant Disease and Immunosuppression | No data available |
|
Cabometyx 20mg tablets
0801050BRBCAAAC
|
Cabometyx | Cabozantinib | Malignant Disease and Immunosuppression | No data available |
|
Cabometyx 40mg tablets
0801050BRBCABAD
|
Cabometyx | Cabozantinib | Malignant Disease and Immunosuppression | No data available |
|
Cabometyx 60mg tablets
0801050BRBCACAE
|
Cabometyx | Cabozantinib | Malignant Disease and Immunosuppression | No data available |
|
Cabozantinib 20mg capsules
0801050BRAAAAAA
|
Cabozantinib | Cabozantinib | Malignant Disease and Immunosuppression | No data available |
|
Cabozantinib 20mg capsules and Cabozantinib 80mg capsules
0801050BRAAABAB
|
Cabozantinib | Cabozantinib | Malignant Disease and Immunosuppression | No data available |
|
Cabozantinib 20mg tablets
0801050BRAAACAC
|
Cabozantinib | Cabozantinib | Malignant Disease and Immunosuppression | No data available |
|
Cabozantinib 40mg tablets
0801050BRAAADAD
|
Cabozantinib | Cabozantinib | Malignant Disease and Immunosuppression | No data available |
|
Cabozantinib 60mg tablets
0801050BRAAAEAE
|
Cabozantinib | Cabozantinib | Malignant Disease and Immunosuppression | No data available |
|
Caelyx pegylated liposomal 20mg/10ml concentrate for inf
0801020K0BDAAAF
|
Caelyx | Doxorubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Caelyx pegylated liposomal 50mg/25ml concentrate for inf
0801020K0BDABAG
|
Caelyx | Doxorubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Calcium folinate 100mg/10ml solution for injection vials
0801000I0AAATAT
|
Calcium folinate (Antimetabolite) | Calcium folinate | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.